Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:177
作者
Gould, TD [1 ]
Quiroz, JA [1 ]
Singh, J [1 ]
Zarate, CA [1 ]
Manji, HK [1 ]
机构
[1] NIMH, Mol Pathophysiol Lab, NIH, Bethesda, MD 20892 USA
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
10.1038/sj.mp.4001518
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bipolar disorder afflicts approximately 1 - 3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: ( 1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); ( 2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site ( inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes ( succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine ( sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:22
相关论文
共 264 条
[31]   GSK3β signalling:: Casting a wide net in Alzheimer's disease [J].
Bhat, RV ;
Budd, SL .
NEUROSIGNALS, 2002, 11 (05) :251-261
[32]   Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures [J].
Biber, K ;
Walden, J ;
GebickeHarter, P ;
Berger, M ;
vanCalker, D .
BIOLOGICAL PSYCHIATRY, 1996, 40 (07) :563-567
[33]   Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins [J].
Blakely, RD ;
Ramamoorthy, S ;
Schroeter, S ;
Qian, Y ;
Apparsundaram, S ;
Galli, A ;
DeFelice, LJ .
BIOLOGICAL PSYCHIATRY, 1998, 44 (03) :169-178
[34]   STRUCTURE OF INOSITOL MONOPHOSPHATASE, THE PUTATIVE TARGET OF LITHIUM-THERAPY [J].
BONE, R ;
SPRINGER, JP ;
ATACK, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10031-10035
[35]   Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and-2 in rat brain [J].
Bosetti, F ;
Weerasinghe, GR ;
Rosenberger, TA ;
Rapoport, SI .
JOURNAL OF NEUROCHEMISTRY, 2003, 85 (03) :690-696
[36]   Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E2 concentration in rat brain [J].
Bosetti, F ;
Rintala, J ;
Seemann, R ;
Rosenberger, TA ;
Contreras, MA ;
Rapoport, SI ;
Chang, MC .
MOLECULAR PSYCHIATRY, 2002, 7 (08) :845-850
[37]   A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder [J].
Bowden, CL ;
Calabrese, JR ;
Sachs, G ;
Yatham, LN ;
Asghar, SA ;
Hompland, M ;
Montgomery, P ;
Earl, N ;
Smoot, TM ;
DeVeaugh-Geiss, J .
ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (04) :392-400
[38]   Low glial numbers in the amygdala in major depressive disorder [J].
Bowley, MP ;
Drevets, WC ;
Öngür, D ;
Price, JL .
BIOLOGICAL PSYCHIATRY, 2002, 52 (05) :404-412
[39]  
BRUNO V, 1995, FUNCT NEUROL, V10, P121
[40]  
BUZSAKI G, 1992, EPILEPSY RES, P279